• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

THALIDOMIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • THALIDOMIDE chembl:CHEMBL468 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    TALIDEX
    K-17
    THALIDOMIDE
    NSC-66847
    NSC-527179
    THALOMID
    THALIDOMIDE
    (±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
    Α-(N-PHTHALIMIDO)GLUTARIMIDE
    (±)-THALIDOMIDE
    Α-PHTHALIMIDOGLUTARIMIDE
    (+-)-THALIDOMIDE
    TALIDOMIDA
    Α-N-PHTHALYLGLUTARAMIDE
    N-PHTHALYL-GLUTAMINSAEURE-IMID
    N-PHTHALYLGLUTAMIC ACID IMIDE
    1,3-DIOXO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE
    2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE
    (+-)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
    3-PHTHALIMIDOGLUTARIMIDE
    ALPHA-(N-PHTHALIMIDO)GLUTARIMIDE
    THALIDOMIDUM
    N-PHTHALOYLGLUTAMIMIDE
    ALPHA-N-PHTHALYLGLUTARAMIDE
    N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
    drugbank:01041
    chembl:CHEMBL468
    rxcui:10432
    pubchem.compound:5426
    chemidplus:50-35-1

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    Year of Approval approved before 1982
    Drug Class leprostatic agents
    Drug Class immunosuppressive agents
    (3 More Sources)

    Publications:

    Vacca et al., 2005, Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma., J. Clin. Oncol.
    Deeken JF et al., 2010, A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform., Pharmacogenomics J
    Yasui et al., 2005, Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation., Curr. Pharm. Des.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Wiedmann et al., 2005, Molecularly targeted therapy for gastrointestinal cancer., Curr Cancer Drug Targets
    Hada et al., 2004, [A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan]., Gan To Kagaku Ryoho
    Payvandi et al., 2004, Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner., Cell. Immunol.
    Du et al., 2005, Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis., Vascul. Pharmacol.
    Horrobin, 2003, A low toxicity maintenance regime, using eicosapentaenoic acid and readily available drugs, for mantle cell lymphoma and other malignancies with excess cyclin D1 levels., Med. Hypotheses
    Kim et al., 2011, Thalidomide: the tragedy of birth defects and the effective treatment of disease., Toxicol. Sci.
    Zhu et al., 2013, Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma., Leuk. Lymphoma
    Rajkumar, 2001, Thalidomide in the treatment of multiple myeloma., Expert Rev Anticancer Ther
    Enomoto et al., 2002, Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production., Gastroenterology
    Vescovo et al., 2002, Effect of thalidomide on the skeletal muscle in experimental heart failure., Eur. J. Heart Fail.
    Turk et al., 1996, Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production., Proc. Natl. Acad. Sci. U.S.A.
    Fu et al., 2002, Thalidomide and tuberculosis., Int. J. Tuberc. Lung Dis.
    Richardson et al., 2002, Thalidomide in multiple myeloma., Biomed. Pharmacother.
    do Socorro Silva Costa P et al., 2019, <i>NR3C1</i>, <i>ABCB1</i>, <i>TNF</i> and <i>CYP2C19</i> polymorphisms association with the response to the treatment of erythema nodosum leprosum., Pharmacogenomics
    Minnema et al., 2003, Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment., J. Thromb. Haemost.
    Li et al., 2002, [Influence of thalidomide on interleukin-6 and its transmission in multiple myeloma patients]., Zhonghua Zhong Liu Za Zhi
    Schlenzka et al., 2004, Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma., Anticancer Drugs
    Eichholz et al., 2010, Anti-angiogenesis therapies: their potential in cancer management., Onco Targets Ther
    Tsambaos et al., 1994, Effects of oral thalidomide on rat liver and skin microsomal P450 isozyme activities and on urinary porphyrin excretion: interaction with oral hexachlorobenzene., Arch. Dermatol. Res.
    Cibeira MT et al., 2011, Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide., Leuk Res
    Kaushal et al., 2004, Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology., J. Thromb. Haemost.
    Shannon et al., 1994, Thalidomide does not perturb CD2, CD4, CD5, CD8, HLA-DR, or HLA-A, B, C molecules in vitro on the membranes of cells with immune potential., Immunopharmacol Immunotoxicol
    Wróbel T et al., 2017, <i>bFGF</i> Polymorphism Is Associated with Disease Progression and Response to Chemotherapy in Multiple Myeloma Patients., Anticancer Res
    Butrym A et al., 2015, Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment., Leuk Res
    Juffermans et al., 2000, Thalidomide suppresses Up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD4+ T cells in humans., J. Infect. Dis.
    Settles et al., 2001, Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide., Cell. Mol. Biol. (Noisy-le-grand)
  • THALIDOMIDE   SNORD68

    Interaction Score: 1.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • THALIDOMIDE   SPG7

    Interaction Score: 1.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • THALIDOMIDE   RPL13

    Interaction Score: 1.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • THALIDOMIDE   SULT1C4

    Interaction Score: 1.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • THALIDOMIDE   CHST3

    Interaction Score: 1.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • THALIDOMIDE   CYP4B1

    Interaction Score: 1.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • THALIDOMIDE   ABCC6

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • THALIDOMIDE   XRCC5

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21435719


    Sources:
    PharmGKB

  • THALIDOMIDE   SLC10A2

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • THALIDOMIDE   CRBN

    Interaction Score: 0.71

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

    PMIDs:
    22966948


    Sources:
    ChemblInteractions

  • THALIDOMIDE   DDB1

    Interaction Score: 0.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • THALIDOMIDE   CUL4A

    Interaction Score: 0.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • THALIDOMIDE   ATP7A

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • THALIDOMIDE   IL6R

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12515619


    Sources:
    NCI

  • THALIDOMIDE   GSTT1

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21435719


    Sources:
    PharmGKB

  • THALIDOMIDE   RBX1

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • THALIDOMIDE   HGF

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15939924


    Sources:
    NCI

  • THALIDOMIDE   TNF

    Interaction Score: 0.26

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Thalomid

    PMIDs:
    12113124 12105857 12167383 8755512 11752352 12102294 12046682


    Sources:
    TdgClinicalTrial TEND TTD

  • THALIDOMIDE   VWF

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12871448


    Sources:
    NCI

  • THALIDOMIDE   F2R

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14995997


    Sources:
    NCI

  • THALIDOMIDE   CTNNB1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26521987


    Sources:
    PharmGKB

  • THALIDOMIDE   ERCC1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21435719


    Sources:
    PharmGKB

  • THALIDOMIDE   CTLA4

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10823791


    Sources:
    NCI

  • THALIDOMIDE   NAT2

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • THALIDOMIDE   ITGB2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11838958


    Sources:
    NCI

  • THALIDOMIDE   FCGR3B

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15457133


    Sources:
    NCI

  • THALIDOMIDE   FGF2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28373444


    Sources:
    PharmGKB

  • THALIDOMIDE   PTGS2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Thalomid
    Novel drug target Established target

    PMIDs:
    15892618 15446566 15598423 15982930 12710892 21507989


    Sources:
    TdgClinicalTrial

  • THALIDOMIDE   FCGR3A

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15457133


    Sources:
    NCI

  • THALIDOMIDE   HLA-B

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7876469


    Sources:
    NCI

  • THALIDOMIDE   FGFR2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Thalomid
    Novel drug target Established target

    PMIDs:
    20616958


    Sources:
    TdgClinicalTrial TEND

  • THALIDOMIDE   NFKB1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Thalomid
    Novel drug target Established target

    PMIDs:
    15723633 11752352


    Sources:
    TdgClinicalTrial TEND

  • THALIDOMIDE   PPARD

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • THALIDOMIDE   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31124417


    Sources:
    PharmGKB

  • THALIDOMIDE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7979550


    Sources:
    NCI

  • TEND: THALIDOMIDE

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Drug Class immunosuppressive agents
    Drug Class leprostatic agents
    Year of Approval approved before 1982

    Publications:

  • TdgClinicalTrial: THALIDOMIDE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: THALIDOMIDE

    • Version: 14-September-2017

    Alternate Names:
    C870 NCI drug code

    Drug Info:

    Publications:
    Vacca et al., 2005, Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma., J. Clin. Oncol.
    Schlenzka et al., 2004, Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma., Anticancer Drugs
    Juffermans et al., 2000, Thalidomide suppresses Up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD4+ T cells in humans., J. Infect. Dis.

  • PharmGKB: thalidomide

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Deeken JF et al., 2010, A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform., Pharmacogenomics J
    Cibeira MT et al., 2011, Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide., Leuk Res
    Butrym A et al., 2015, Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment., Leuk Res

  • TTD: Thalidomide

    • Version: 2020.06.01

    Alternate Names:
    D0U7GK TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL468

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL468

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21